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 Introduction 
 Mitochondrial DNA (mtDNA) depletion syndrome 
(MDS) is a clinically heterogeneous group of disorders, 
defined as having quantitative reduction in mtDNA copy 
number  [1] . The size and sequence of the mtDNA are gen-
erally normal. Reduction in mtDNA quantity leads to in-
sufficient synthesis of respiratory chain complexes I, III, 
IV and V  [1–4] . The human mitochondrial electron trans-
port chain consists of five enzymatic complexes, ubiqui-
none and cytochrome c. The main function is to transfer 
electrons through intramolecular redox centers of com-
plexes I through IV, with the production of ATP by the 
fifth enzymatic complex. Except for complex II, which is 
encoded entirely by nuclear genes, all respiratory chain 
complexes are encoded, at least in part, by mtDNA, which 
encodes a total of 13 proteins, all of whom are present in 
respiratory chain complex I, III, IV and V. Nuclear-en-
coded proteins/enzymes are required for both enzymat -
 ic complexes and for replication and maintenance of 
mtDNA.
 Key Words 
 Mitochondrial depletion   Prenatal ultrasound   Fetal 
magnetic resonance imaging   Brain pseudocyst 
 Abstract 
 We report the prenatal ultrasound and magnetic resonance 
imaging finding of periventricular, large subependymal 
pseudocysts (SEPCs) in a patient who was later diagnosed as 
having mitochondrial depletion syndrome (MDS). To our 
knowledge, this is the first report of fetal SEPCs in a patient 
with MDS. These findings may provide an important diag-
nostic tool for prenatal diagnosis of MDS in at risk pregnan-
cies when the gene mutation causing the condition has not 
been delineated. It may also direct the neonatologist in the 
postnatal care of the newborn detected prenatally with 
SEPCs in view of the association of this finding with infection, 
chromosome abnormalities, metabolic disorders and other 
abnormalities, when such findings are identified serendipi-
tously. Further research is needed to find if the SEPCs de-
tected in our patient is an association or a coincidental find-
ing.  Copyright © 2009 S. Karger AG, Basel 
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 Mutations in 5 nuclear genes have been identified thus 
far in patients with MDS  [5] . The disease may affect mul-
tiple or single organs, e.g. liver and/or muscle and brain 
and/or heart and kidney, with onset of symptoms usually 
in the first year of life. Most affected patients die in early 
childhood  [4–6] ( table 1 ). Mutations in the thymidine ki-
nase 2 gene  (TK2) , located on chromosome 16q22  [7–9] , 
were found to be associated with a myopathic form of the 
syndrome, whereas mutations in the deoxyguanosine ki-
nase gene  (DGUOK) on chromosome 2p13  [10–18] and 
polymerase-  gene  (POLG1)  [19–22] have been implicat-
ed in the hepatocerebral form. Thymidine phosphorylase 
 (TP) defects were found in some cases with leukodystro-
phy and a gastrointestinal disorder  [23] , and most recent-
ly, mutations in the succinyl-coenzyme A synthase gene 
 (SUCLA2) were identified in 4 infants with severe devel-
opmental delay, epilepsy, hearing loss, anemia and Leigh-
like lesions on brain magnetic resonance imaging (MRI) 
 [24] . In addition, adenine nucleotide translocator 1 
 (ANT1) and mitochondrial replicative helicase  Twinkle , 
both affecting mtDNA stability, were found to be in-
volved in some cases of mtDNA depletion  [25] . Biochem-
ical analyses of the affected tissues generally show low 
activity of all four mitochondrial respiratory chain com-
plexes I, III, IV and V, and Southern blot analysis or quan-
titative polymerase chain reaction (PCR) characteristi-
cally reveals a severe reduction in the ratio of mtDNA to 
nuclear DNA.
 We report the finding of periventricular cysts on fetal 
brain ultrasound and MRI in a patient who postnatally 
was found to have MDS with 90% depletion of mtDNA 
in muscle. Although this can be a coincidental finding, 
in view of previous publications of this finding in other 
metabolic disorders  [26, 27] , we hypothesize that this 
might be a true association which can help in the prenatal 
diagnosis of this condition in at risk pregnancy, when the 
gene mutation causing the condition is not known.
 Case Report 
 A nonconsanguineous Chinese couple was referred for coun-
seling regarding their previous pregnancy, which resulted in neo-
natal death, in China, of a son who died at 2 days of age of an un-
known etiology. The mother was a 30-year-old G2P1L1 woman at 
13 weeks and 5 days of gestation when seen by us. The pregnancy 
was uncomplicated initially, and an ultrasound examination at 11 
weeks and 5 days showed a single intrauterine pregnancy with a 
nuchal translucency of 2.7 mm. First trimester screening was not 
done and maternal serum screening showed negative screening 
for open neural tube defect and Down syndrome (the   -fetopro-
tein was 1.69 multiples of median). The couple decided to have an 
amniocentesis in view of their past obstetrical history of early 
neonatal death; this was performed at 17 weeks of gestation and 
showed a normal male karyotype (46, XY). Fetal ultrasound per-
formed at the same time revealed bilateral ventriculomegaly and 
right renal pyelectasis of 4.9 mm. The rest of the fetal anatomy 
appeared normal. Fetal echocardiography performed at 20 weeks 
of gestation showed normal intracardiac anatomy with balanced 
Table 1. Comparison between the clinical and laboratory manifestations of MDS and methylmalonic acidemia
Case 1 [40] Case 2 [40] Present case
Urine organic acids analysis
Organic acids found elevated
Methylmalonic acid
3-hydroxypropionic
3-hydroxyvaleric
Methylmalonic
3-methylglutaconic
2-oxoglutaric acid
Methylmalonic acid
3-hydroxypropionic
3-hydroxyvaleric
Methylmalonic
3-methylglutaconic
2-oxoglutaric acid
Methylmalonic acid
3-hydroxypropionic
3-hydroxyvaleric
Dicarboxylic acid
3-hydroxybutyric
Plasma acylcarnitines – – propionylcarnitine methylmalonylcarnitine
Plasma amino acids normal normal normal
Onset of lactic acidosis 5th month of life 11th month of life 2nd day of life
Opthamological exam bilateral papillary edema – normal
Brain imaging, MRI/CT frontal lobe atrophy
normal myelination
diffuse cortical atrophy bilateral periventricular pseudocysts and 
normal myelination
Course death at 3 years of age death at 3 years of age death at 7 days of life
Ethnic background Hispanic Hispanic Chinese
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four-chamber view and normally related great vessels. Fetal ultra-
sound at 19 weeks’ gestation showed a string of multilocular cys-
tic spaces in the anterior subependymal caudothalamic region. 
Subsequent fetal ultrasound examination at 25 weeks of gestation 
demonstrated normal lateral ventricular size and normal renal 
ultrasound bilaterally; however, bilateral periventricular/subep-
endymal cysts adjacent to the frontal horns were again seen 
( fig. 1 ). Fetal MRI confirmed the presence of the atypical cysts 
and noted that the remaining cerebral anatomy was normal 
( fig. 2 ). The cysts were extensive, paralleling the anterior horns 
and bodies of the lateral ventricles. Diffusion-weighted imaging 
and ADC maps demonstrated multifocal restriction in the brain 
substance adjacent to the cystic lesion. On follow-up ultrasound 
at 27 weeks of gestation, the cysts were located lateral to the cau-
date measuring 17  ! 3 mm on the right and 14  ! 7 mm on the 
left. At 33 weeks’ gestation, the cysts increased in size to 16  ! 
6 mm on the right and 23  ! 8 mm on the left side. Also, fetal 
weight estimates decreased from the 50th percentile to the 20th 
percentile. PCR for cytomegalovirus (CMV) done on the amni-
otic fluid sample obtained previously was negative and maternal 
screening for  Toxoplasma gondii , other viruses (HIV, measles, 
and more), rubella,  CMV, and herpes simplex (TORCH) analysis 
showed no evidence for an acute infection.
 Delivery was induced at 37 weeks, because of intrauterine 
growth retardation (IUGR). The birth weight was 2,330 g (10–
25th percentile) and the birth length was 46 cm (25th percentile). 
Apgar scores were 9 and 9 at 1 and 10 min, respectively. On the 
2nd day of life, the infant developed persistent tachypnea and se-
vere lactic acidosis (lactate 21.1 m M , pH 7.0, PCO 2 31 mm Hg, bi-
carbonate 8 m M and base excess of –8 m M ) and a lactate to pyru-
vate ratio of 56.5 and the plasma CK values were normal. Initial 
urinary organic acids analysis was normal; however, analysis of 
subsequent samples revealed a high concentration of methylma-
lonic acid, as well as smaller amounts of methylcitrate and 3-hy-
droxypropionic acid. Analysis of the plasma acylcarnitines pro-
file, run at the same time, showed the presence of propionylacyl-
carnitine and methylmalonylcarnitine ( table 1 ). Septic workup 
showed no evidence for an underlying infection as the cause for 
the persistent lactic acidosis. In addition, echocardiography con-
firmed normal cardiac anatomy. Brain MRI at day 6 of life con-
firmed the prenatal findings, with bilateral periventricular cysts 
and high lactate peak on magnetic resonance spectroscopy. Ab-
normalities previously seen on diffusion-weighted imaging had 
normalized.
 The differential diagnosis at this point included methylmalo-
nic aciduria (MMA), congenital lactic acidosis caused by defects 
in pyruvate carboxylase or pyruvate dehydrogenase, or a defect in 
the mitochondrial respiratory chain activity. Empiric therapy for 
pyruvate dehydrogenase and pyruvate carboxylase with thiamine 
and biotin, as well as with carnitine and vitamin B 12 , and high-
dose glucose infusion for MMA was started. Insulin was admin-
istered in an effort to maintain plasma glucose levels below 10 
mmol/l as well as a continuous bicarbonate infusion to correct 
acidosis. In spite of this intensive treatment, the plasma lactate 
climbed to 23 mmol/l. He was started on dobutamine for cardio-
vascular support, but did not respond to these therapeutic mea-
sures and died at day 7 of life.
 Methods 
 Muscle tissue was obtained on day 3 of life from quadriceps 
and examined by routine light and electron microscopy. The ac-
tivities of citrate synthase and complexes I–V were determined in 
the mitochondria-enriched fraction of the quadriceps muscle, us-
ing standard polarographic and spectrophotometric methods 
 [28] . Quantitative PCR analysis done on DNA isolated from mus-
cle was performed as described  [29] . Plasma acylcarnitine profiles 
were analyzed using tandem mass spectroscopy, and urine or-
ganic acids were quantified using gas chromatography-mass 
spectrometry. DNA analyses for  TK2 ,  POLG , and SUCLA2 were 
performed as previously described  [9] .  ANT1 and  Twinkle muta-
tion analysis was done as described by Naimi et al.  [25] .
ba
 Fig. 1. Fetal ultrasound at 25 weeks’ gestation showing bilateral 
subependymal cysts (arrows). 
 Fig. 2. Fetal MRI at 25 weeks’ gestation showing bilateral peri-
v entricular cysts (arrows).  a Fetal axial single-shot fast spin echo. 
 b Diffusion-weighted imaging. 
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 Results 
 Biochemical analysis of muscle tissue showed NADH-
cytochrome c reductase activity of 0.18   mol/min/g (con-
trol 0.77  8 0.12; normal range 0.5–1.9), and NADH-cy-
tochrome c reductase to citrate synthase activity ratio of 
9.7% (normal  1 10%), succinate cytochrome c reductase 
activity of 0.35   mol/min/g (control 1.43  8 0.46; normal 
range 0.57–2.3), and succinate cytochrome c reductase to 
citrate synthase activity ratio of 13.8% (normal  1 18%), 
cytochrome oxidase activity of 0.14   mol/min/g (control 
1.48  8 0.57; normal range 0.58–2.5), and cytochrome ox-
idase to citrate synthase activity ratio of 5.5% (normal 
 1 11%), and citrate synthase activity was 2.52   mol/min/g 
(control 3.35  8 1.11; normal range 0.8–5.5). Electron mi-
croscopy of muscle and skin demonstrated normal num-
bers of mitochondria and normal mitochondrial struc-
ture. There was no evidence of ragged red fibers on his-
tochemical staining and no Cox negative fibers were 
observed. Quantitative PCR clearly demonstrated signif-
icant reduction (approximately 90%) of mtDNA when 
compared to nuclear DNA, as compared with controls. 
Mutation analysis of the genes  TK2 ,  ANT1 ,  POLG ,
 SUCLA2 and mitochondrial replicative helicase  Twinkle 
genes done by sequencing of the genes did not identify a 
mutation.
 Discussion 
 Subependymal pseudocysts (SEPCs), also known as 
germinolytic cysts, are etiologically heterogeneous find-
ings. They are called pseudocysts since they lack a mem-
brane. They are probably the result of an injury to the 
periventricular subependymal germinal matrix mostly 
due to hemorrhage, infarction or intrauterine infection 
 [30] . In a retrospective study by Shen and Huang  [31] , 
SEPCs were detected in 0.5–5.2% of neonates with 18/25 
cases not known to be associated with a known perinatal 
insult. However, a more recent article by Heibel et al.  [32] 
showed that the incidence is 0.35% (34/1,000) with 4/34 
developing symptoms (hemiparesis and infantile spasm). 
In 2001, Makhoul et al.  [33] reported 10 cases with SEPCs 
among the sick newborns admitted to the neonatal inten-
sive care unit. Four of the 10 had CMV infection and 2 
had other abnormalities. These authors also performed a 
meta-analysis of previously reported cases and concluded 
that if the pseudocysts are not associated with congenital 
abnormalities, IUGR, intrauterine infections or chromo-
some abnormalities, the prognosis is good. However, 
these factors cannot be separated completely since infec-
tions, multiple abnormalities and chromosome abnor-
malities can also result in IUGR. The SEPC was also
reported in association with two inborn errors of me-
tabolism known to cause brain dysgenesis: Zellweger 
syndrome  [26, 27] and holocarboxylase synthase defi-
ciency  [34] , and our case adds to the increasing number 
of conditions associated with SEPCs, known to have poor 
prognosis. Thus, since SEPC is not a benign finding in 
many of the cases, and since it is prenatal in origin, its 
finding in a fetus should be thoroughly investigated to try 
and detect the etiology and thus the prognosis. To the 
best of our knowledge, our report is the first to document 
the findings of fetal ultrasound and MRI in a case with 
MDS as well as the first to show the finding of SEPC in 
this condition.
 The patient reported by us presented with persistent, 
severe lactic acidosis and MMA on day 2 of life and had 
been shown to have cystic lesions in the anterior subep-
endymal caudothalamic region of the brain on prenatal 
ultrasound and MRI starting as early as 19 weeks’ gesta-
tion. Differential diagnosis initially included MMA based 
on the findings on acylcarnitine profiles in plasma. How-
ever, an increased lactate to pyruvate ratio in plasma sug-
gested congenital lactic acidosis caused, for example, by 
a defect in the mitochondrial electron transfer chain, or 
by MDS, given the severe reduction in mtDNA in muscle 
tissue. Recently, it has been reported that defects in mito-
chondrial energy metabolism are often associated with 
elevated citric acid (TCA) cycle intermediates, in particu-
lar elevated urinary 3-methylglutaconic acid  [35] , dicar-
boxylic acids  [36] , or a combination of elevated dicarbox-
ylic acids, 2-oxoglutarate, ethylmalonate and 3-methyl-
glutaconate  [37] , elevated lactate, 3-hydroxybutyrate and 
acetoacetate  [38] , elevated 3-methylglutaconate and 3-
methylglutarate  [39] . Two unrelated cases of infantile 
MDS associated with MMA were reported  [40] . Both pa-
tients had unremarkable pregnancies, but presented with 
lactic acidosis after a short symptom-free interval, as well 
as clinical features of muscle weakness, hypotonia and 
developmental delay. Muscle biopsy in each case demon-
strated partial respiratory chain enzyme deficiency of cy-
tochrome-oxidase with raised citrate synthase activity in 
one patient and decreased activities of multiple complex-
es in the other. The results of the analysis of the amount 
of mtDNA in the muscle tissue was in keeping with deple-
tion of mtDNA, 24 and 39%, respectively, of the mean 
control value. Patient 2 died at the age of 3 years with se-
vere metabolic acidosis and pneumonia. The mechanism 
of the increased excretion of methylmalonic acid and 
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 related organic acids remained unknown. This report 
shares some clinical features with our case; however, the 
brain MRI and ophthalmological findings were different 
( table 1 ).
 The finding of isolated SEPCs on fetal ultrasound as 
early as 19 weeks of gestation, as seen in our patient, and 
confirmed on prenatal and postnatal MRI, is the only 
prenatal imaging finding reported so far in association 
with MDS. MDS is a heterogeneous group of conditions 
affecting multiple or single organs. Clinically, it presents 
as a hepatocerebral form, a myopathic form, or a variant 
in which the dominant problem is cardiomyopathy. Vari-
ants of these conditions have been reported with differ-
ences in age at onset, organs involved, clinical course, and 
laboratory findings. Recently, mutations in  TK2 ,  DGUOK , 
 POLG1 ,  TP ,  ANT1 and  Twinkle have been reported in as-
sociation with MDS. The majority of patients with MDS 
show deficiencies in more than one respiratory chain 
complex, particularly complex I, II and IV. Complex II is 
usually spared since it is encoded solely by nuclear DNA. 
As in the case reported by Yano et al.  [40] , our patient had 
decreased activities of multiple complexes with respect to 
citrate synthase, including complex II, suggesting a sec-
ondary deficiency of nuclear-encoded enzymes. The ob-
servation of no Cox-negative fibers on the muscle cross-
section might be related to the very young age of our 
 patient at the time of muscle biopsy as most of the Cox-
negative fibers in MDS are found in older patients. The 
increased urinary secretion of methylmalonic acid is un-
clear, but the diagnosis of primary MMA was excluded. 
Methylmalonic peaks on gas chromatography cannot al-
ways be distinguished from peaks representing succinic 
acid, and accumulation of succinyl-CoA, one of the TCA 
cycle intermediates, would not be surprising in patients 
with mitochondrial energy defects.
 The fact that we were unable to detect any mutations 
in any of the 5 genes known to be associated with MDS, 
and the clinical picture that was different from those pre-
viously found associated with other variants of MDS ( ta-
ble 1 ), suggests that our patient, along with the two re-
cently published cases  [40] , might represent a novel dis-
order associated with this syndrome.
 The pathophysiology of the cerebral pseudocysts 
found in the course of prenatal imaging is also unclear. 
However, it might be the result of prenatal lysis of undif-
ferentiated germinal matrix  [26, 31, 41] , which could be 
the result of the metabolic insult. Further reports are re-
quired to determine if the finding of SEPC in our case is 
an association or a coincidence. If found to be an asso-
ciation, it can help in the prenatal diagnosis of the condi-
tion in at risk pregnancy, when no other tools for prenatal 
diagnosis, such as metabolic or DNA analysis, are avail-
able.
 
 References 
 1 Moraes CT, Shanske S, Tritschler HJ, Aprille 
JR, Andreetta F, Bonilla E, Schon EA, Di-
Mauro S: MtDNA depletion with variable 
tissue expression: a novel genetic abnormal-
ity in mitochondrial diseases. Am J Hum 
Genet 1991; 48: 492–501. 
 2 Hirano M, Vu TH: Defects of intergenomic 
communication: where do we stand? Brain 
Pathol 2000; 10: 451–461. 
 3 DiMauro S, Schon EA: Mitochondrial respi-
ratory-chain diseases. N Engl J Med 2003; 
 348: 2656–2668. 
 4 DiMauro S, Hirano M: Mitochondrial en-
cephalomyopathies: an update. Neuromus-
cul Disord 2005; 15: 276–286. 
 5 Spinazzola A, Zeviani M: Disorders of nucle-
ar-mitochondrial intergenomic signaling. 
Gene 2005; 354: 162–168. 
 6 Carrozzo R, Bornstein B, Lucioli S, Campos 
Y, de la Pena P, Petit N, Dionisi-Vici C, Vilar-
inho L, Rizza T, Bertini E, Garesse R, San-
torelli FM, Arenas J: Mutation analysis in 16 
patients with mtdna depletion. Hum Mutat 
2003; 21: 453–454. 
 7 Saada A, Shaag A, Mandel H, Nevo Y, Eriks-
son S, Elpeleg O: Mutant mitochondrial thy-
midine kinase in mitochondrial DNA deple-
tion myopathy. Nat Genet 2001; 29: 342–344. 
 8 Mancuso M, Salviati L, Sacconi S, Otaegui D, 
Camano P, Marina A, Bacman S, Moraes CT, 
Carlo JR, Garcia M, Garcia-Alvarez M, Mon-
zon L, Naini AB, Hirano M, Bonilla E, Tara-
tuto AL, DiMauro S, Vu TH: Mitochondrial 
DNA depletion: mutations in thymidine ki-
nase gene with myopathy and SMA. Neurol-
ogy 2002; 59: 1197–1202. 
 9 Mancuso M, Filosto M, Bonilla E, Hirano M, 
Shanske S, Vu TH, DiMauro S: Mitochon-
drial myopathy of childhood associated with 
mitochondrial DNA depletion and a homo-
zygous mutation (T77M) in the TK2 gene. 
Arch Neurol 2003; 60: 1007–1009. 
 10 Mandel H, Szargel R, Labay V, Elpeleg O, 
Saada A, Shalata A, Anbinder Y, Berkowitz 
D, Hartman C, Barak M, Eriksson S, Cohen 
N: The deoxyguanosine kinase gene is mu-
tated in individuals with depleted hepatocer-
ebral mitochondrial DNA. Nat Genet 2001; 
 29: 337–341. 
 11 Vu TH, Sciacco M, Tanji K, Nichter C, Bo-
nilla E, Chatkupt S, Maertens P, Shanske S, 
Mendell J, Koenigsberger MR, Sharer L, 
Schon EA, DiMauro S, DeVivo DC: Clinical 
manifestations of mitochondrial DNA de-
pletion. Neurology 1998; 50: 1783–1790. 
 12 Mancuso M, Ferraris S, Pancrudo J, Feigen-
baum A, Raiman J, Christodoulou J, Thor-
burn DR, DiMauro S: New DGK gene mu-
tations in the hepatocerebral form of mito - 
chondrial DNA depletion syndrome. Arch 
Neurol 2005; 62: 745–747. 
 13 Rabinowitz SS, Gelfond D, Chen CK, Glos-
ter ES, Whitington PF, Sacconi S, Salviati L, 
DiMauro S: Hepatocerebral mitochondrial 
DNA depletion syndrome: clinical and mor-
phologic features of a nuclear gene mutation. 
J Pediatr Gastroenterol Nutr 2004; 38: 216–
220. 
 14 Taanman JW, Kateeb I, Muntau AC, Jaksch 
M, Cohen N, Mandel H: A novel mutation in 
the deoxyguanosine kinase gene causing de-
pletion of mitochondrial DNA. Ann Neurol 
2002; 52: 237–239. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 8
:3
0:
28
 A
M
 Rohrbach et al.
 
Fetal Diagn Ther 2009;25:177–182182
 15 Tadiboyina VT, Rupar A, Atkison P, Feigen-
baum A, Kronick J, Wang J, Hegele RA: Nov-
el mutation in DGUOK in hepatocerebral 
mitochondrial DNA depletion syndrome as-
sociated with cystathioninuria. Am J Med 
Genet A 2005; 135: 289–291. 
 16 Wang L, Limongelli A, Vila MR, Carrara F, 
Zeviani M, Eriksson S: Molecular insight 
into mitochondrial DNA depletion syn-
drome in two patients with novel mutations 
in the deoxyguanosine kinase and thymi-
dine kinase 2 genes. Mol Genet Metab 2005; 
 84: 75–82. 
 17 Slama A, Giurgea I, Debrey D, Bridoux D, de 
Lonlay P, Levy P, Chretien D, Brivet M, Le-
grand A, Rustin P, Munnich A, Rotig A: De-
oxyguanosine kinase mutations and com-
bined deficiencies of the mitochondrial 
respiratory chain in patients with hepatic in-
volvement. Mol Genet Metab 2005; 86: 462–
465. 
 18 Labarthe F, Dobbelaere D, Devisme L, De 
Muret A, Jardel C, Taanman JW, Gottrand F, 
Lombes A: Clinical, biochemical and mor-
phological features of hepatocerebral syn-
drome with mitochondrial DNA depletion 
due to deoxyguanosine kinase deficiency. J 
Hepatol 2005; 43: 333–341. 
 19 Naviaux RK, Nguyen KV: Polg mutations as-
sociated with Alpers’ syndrome and mito-
chondrial DNA depletion. Ann Neurol 2004; 
 55: 706–712. 
 20 Naviaux RK, Nyhan WL, Barshop BA, Poul-
ton J, Markusic D, Karpinski NC, Haas RH: 
Mitochondrial DNA polymerase gamma de-
ficiency and mtDNA depletion in a child 
with Alpers’ syndrome. Ann Neurol 1999; 45: 
 54–58. 
 21 Ferrari G, Lamantea E, Donati A, Filosto M, 
Briem E, Carrara F, Parini R, Simonati A, 
Santer R, Zeviani M: Infantile hepatocere-
bral syndromes associated with mutations in 
the mitochondrial DNA polymerase-gam-
maA. Brain 2005; 128: 723–731. 
 22 Davidzon G, Mancuso M, Ferraris S, Quinzii 
C, Hirano M, Peters HL, Kirby D, Thorburn 
DR, DiMauro S: Polg mutations and Alpers 
syndrome. Ann Neurol 2005; 57: 921–923. 
 23 Nishino I, Spinazzola A, Hirano M: Thy-
midine phosphorylase gene mutations in 
MNGIE, a human mitochondrial disorder. 
Science 1999; 283: 689–692. 
 24 Elpeleg O, Miller C, Hershkovitz E, Bitner-
Glindzicz M, Bondi-Rubinstein G, Rahman 
S, Pagnamenta A, Eshhar S, Saada A: Defi-
ciency of the ADP-forming succinyl-CoA 
synthase activity is associated with encepha-
lomyopathy and mitochondrial DNA deple-
tion. Am J Hum Genet 2005; 76: 1081–1086. 
 25 Naimi M, Bannwarth S, Procaccio V, Pouget 
J, Desnuelle C, Pellissier JF, Rotig A, Mun-
nich A, Calvas P, Richelme C, Jonveaux P, 
Castelnovo G, Simon M, Clanet M, Wallace 
D, Paquis-Flucklinger V: Molecular analysis 
of ANT1, TWINKLE and POLG in patients 
with multiple deletions or depletion of mito-
chondrial DNA by a dHPLC-based assay. 
Eur J Hum Genet 2006; 14: 917–922. 
 26 Russel IM, van Sonderen L, van Straaten HL, 
Barth PG: Subependymal germinolytic cysts 
in Zellweger syndrome. Pediatr Radiol 1995; 
 25: 254–255. 
 27 Cuillier F, Cartault F, Lemaire P, Gruau M, 
Alessandri JL: Subependymal pseudocysts 
in the fetal brain revealing Zellweger syn-
drome (in French). J Gynecol Obstet Biol Re-
prod (Paris) 2004; 33: 325–329. 
 28 Rustin P, Chretien D, Bourgeron T, Gerard 
B, Rotig A, Saudubray JM, Munnich A: Bio-
chemical and molecular investigations in re-
spiratory chain deficiencies. Clin Chim Acta 
1994; 228: 35–51. 
 29 Naini A, Shanske S: Detection of mutations 
in mtDNA. Methods Cell Biol 2007; 80: 437–
463. 
 30 Yamashita Y, Outani Y, Kawano Y, Horikawa 
M, Matsuishi T, Hashimoto T: Clinical anal-
yses and short-term prognoses of neonates 
with subependymal cysts. Pediatr Neurol 
1990; 6: 375–378. 
 31 Shen EY, Huang FY: Subependymal cysts in 
normal neonates. Arch Dis Child 1985; 60: 
 1072–1074. 
 32 Heibel M, Heber R, Bechinger D, Kornhuber 
HH: Early diagnosis of perinatal cerebral le-
sions in apparently normal full-term new-
borns by ultrasound of the brain. Neuroradi-
ology 1993; 35: 85–91. 
 33 Makhoul IR, Zmora O, Tamir A, Shahar E, 
Sujov P: Congenital subependymal pseudo-
cysts: own data and meta-analysis of the lit-
erature. Isr Med Assoc J 2001; 3: 178–183. 
 34 Squires L, Betz B, Umfleet J, Kelley R: Reso-
lution of subependymal cysts in neonatal
holocarboxylase synthetase deficiency. Dev 
Med Child Neurol 1997; 39: 267–269. 
 35 Scaglia F, Sutton VR, Bodamer OA, Vogel H, 
Shapira SK, Naviaux RK, Vladutiu GD: Mi-
tochondrial DNA depletion associated with 
partial complex ii and iv deficiencies and 3-
methylglutaconic aciduria. J Child Neurol 
2001; 16: 136–138. 
 36 Salviati L, Sacconi S, Mancuso M, Otaegui D, 
Camano P, Marina A, Rabinowitz S, Shiff-
man R, Thompson K, Wilson CM, Feigen-
baum A, Naini AB, Hirano M, Bonilla E, Di-
Mauro S, Vu TH: Mitochondrial DNA 
depletion and DGK gene mutations. Ann 
Neurol 2002; 52: 311–317. 
 37 Morris AA, Taanman JW, Blake J, Cooper 
JM, Lake BD, Malone M, Love S, Clayton PT, 
Leonard JV, Schapira AH: Liver failure asso-
ciated with mitochondrial DNA depletion. J 
Hepatol 1998; 28: 556–563. 
 38 Macmillan CJ, Shoubridge EA: Mitochon-
drial DNA depletion: prevalence in a pediat-
ric population referred for neurologic evalu-
ation. Pediatr Neurol 1996; 14: 203–210. 
 39 Figarella-Branger D, Pellissier JF, Scheiner 
C, Wernert F, Desnuelle C: Defects of the mi-
tochondrial respiratory chain complexes in 
three pediatric cases with hypotonia and 
cardiac involvement. J Neurol Sci 1992; 108: 
 105–113. 
 40 Yano S, Li L, Le TP, Moseley K, Guedalia A, 
Lee J, Gonzalez I, Boles RG: Infantile mito-
chondrial DNA depletion syndrome associ-
ated with methylmalonic aciduria and 3-
methylcrotonyl-CoA and propionyl-CoA 
carboxylase deficiencies in two unrelated pa-
tients: a new phenotype of mtDNA depletion 
syndrome. J Inherit Metab Dis 2003; 26: 481–
488. 
 41 Shaw CM, Alvord EC Jr: Subependymal ger-
minolysis. Arch Neurol 1974; 31: 374–381. 
 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 8
:3
0:
28
 A
M
